Zenith Epigenetics
CompanyCanada
Zenith Epigenetics develops one asset, in phase 2 (ZEN-3694 in NUT carcinoma). Mostly small molecule acting on epigenetic regulation of gene expression and BRD4; based in Canada.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
1Inhibits BET bromodomain proteins to regulate oncogenic gene transcription
Phase 2, Small molecule, Epigenetic regulation of gene expression, BRD4, NUT carcinoma
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Similar companies6